Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (5,817,000)	$ (3,661,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment	9,000	11,000
Amortization of patent, trademark rights	49,000	36,000
Amortization of Debt Discount and Other Expenses	73,000
Non-cash lease expense	(67,000)	37,000
Gain from sale of income tax operating losses		(255,000)
Equity-based compensation	80,000	82,000
Loss (gain) on sale of marketable investments	92,000	(203,000)
Change in assets and liabilities:
Funds receivable from New Jersey net operating loss	1,184,000
Prepaid expenses and other current assets and other non-current assets	(62,000)	(180,000)
Lease liability	60,000	(23,000)
Accounts payable	124,000	586,000
Accrued expenses	(540,000)	(110,000)
Net cash used in operating activities	(4,815,000)	(3,680,000)
Cash flows from investing activities:
Proceeds from sale of marketable investments	50,000	598,000
Purchase of marketable investments	(158,000)	(712,000)
(Purchase) abandonment of patent and trademark rights	(50,000)	7,000
Proceeds from sales of property and equipment		29,000
Net cash used in investing activities	(158,000)	(78,000)
Cash flows from financing activities:
Proceeds from sale of stock, net of issuance costs	329,000	100,000
Proceeds from note payable, net of issuance costs	2,500,000
Net cash provided by financing activities	2,829,000	100,000
Net decrease in cash and cash equivalents	(2,144,000)	(3,658,000)
Cash and cash equivalents at beginning of period	5,439,000	27,053,000
Cash and cash equivalents at end of period	3,295,000	23,395,000
Supplemental disclosures of non-cash investing and financing cash flow information:
Conversion of Series B preferred		$ 4,000